EU Proposal To Address Impact Of Duplicate Marketing Authorizations On Biosimilars Availability
Executive Summary
The European Commission has proposed updating its guidance on duplicate marketing authorizations to address concerns regarding the availability of biosimilars.
You may also be interested in...
EU updates note on issuing duplicate drug marketing authorisations
The European Commission has issued a revised note on how it handles requests from pharmaceutical companies for duplicate marketing authorisations1,2. The revised note, among other things, attempts to clarify a misunderstanding by applicants of the term "true duplicate" in the March 2010 version of the document3,4.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.